MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/keaa825

Медицинская библиотека · Rheumatology (Oxford, England) · 2021

Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis.

Lindström Ulf, Glintborg Bente, Di Giuseppe Daniela, Schjødt Jørgensen Tanja, Gudbjornsson Bjorn, Lederballe Grøn Kathrine, Aarrestad Provan Sella, Michelsen Brigitte, Lund Hetland Merete, Wallman Johan K, Nordström Dan, Trokovic Nina, Love Thorvardur Jon, Krogh Niels Steen, Askling Johan, Jacobsson Lennart T H, Kristensen Lars Erik

Сравнительное исследованиеСтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

To compare treatment retention and response to secukinumab vs adalimumab, including the other four TNF inhibitors (TNFi) as comparators, in PsA.

METHODS

All patients with PsA starting secukinumab or a TNFi in 2015-2018 were identified in the biologic registers of the Nordic countries. Data on comorbidities were linked from national registers. One-year treatment retention and hazard ratios (HRs) for treatment discontinuation were calculated. The proportion achieving a 6 month 28-joint Disease Activity Index for Psoriatic Arthritis (DAPSA28) remission was determined together with odds ratios (ORs) for remission (logistic regression). Both HRs and ORs were calculated with adalimumab as the reference and adjusted for baseline characteristics and concurrent comorbidities. All analyses were stratified by the line of biologic treatment (first, second, third+).

RESULTS

We identified 6143 patients contributing 8307 treatment courses (secukinumab, 1227; adalimumab, 1367). Secukinumab was rarely used as the first biologic, otherwise baseline characteristics were similar. No clinically significant differences in treatment retention or response rates were observed for secukinumab vs adalimumab. The adjusted HRs for discontinuation per the first, second and third line of treatment were 0.98 (95% CI 0.68, 1.41), 0.94 (0.70, 1.26) and 1.07 (0.84, 1.36), respectively. The ORs for DAPSA28 remission in the first, second and third line of treatment were 0.62 (95% CI 0.30, 1.28), 0.85 (0.41, 1.78) and 0.74 (0.36, 1.51), respectively. In the subset of patients previously failing a TNFi due to ineffectiveness, the results were similar.

CONCLUSION

No significant differences in treatment retention or response were observed between secukinumab and adalimumab, regardless of the line of treatment. This suggests that even in patients who have failed a TNFi, choosing either another TNFi or secukinumab may be equally effective.

Для цитирования: Lindström Ulf, Glintborg Bente, Di Giuseppe Daniela, Schjødt Jørgensen Tanja, Gudbjornsson Bjorn, Lederballe Grøn Kathrine, Aarrestad Provan Sella, Michelsen Brigitte, Lund Hetland Merete, Wallman Johan K, Nordström Dan, Trokovic Nina, Love Thorvardur Jon, Krogh Niels Steen, Askling Johan, Jacobsson Lennart T H, Kristensen Lars Erik. Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis.. Rheumatology (Oxford, England). 2021. DOI: 10.1093/rheumatology/keaa825.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.